Efficacy of Intravenous Tissue-Type Plasminogen Activator in Central Retinal Artery Occlusion
Stroke2011Vol. 42(8), pp. 2229–2234
Citations Over TimeTop 10% of 2011 papers
Celia S. Chen, Andrew W. Lee, Bruce Campbell, Tien Lee, Mark Paine, Clare L. Fraser, John Grigg, Romesh Markus
Abstract
Although essentially a negative study, it does add to the evidence base of reperfusion in central retinal artery occlusion by showing that the time window for intervention is likely to be <6 hours. Reocclusion is a potential problem and may require adjuvant anticoagulation. Future studies should concentrate on determining the efficacy of thrombolytics in the <6-hour time window. Clinical Trial Registration- URL: http://www.anzctr.org.au. Unique identifier: 83102.
Related Papers
- → Combined Central Retinal Artery Occlusion (CRAO) and Central Retinal Vein Occlusion (CRVO) in a Celiac Disease Patient: A Case Report(2024)1 cited
- → Traumatic optic neuropathy with combined central retinal artery occlusion (CRAO) and central retinal vein occlusion (CRVO) following blunt ocular trauma(2014)3 cited
- Combined occlusion of the central retinal artery and vein.(1994)
- → Sequential treatment of central retinal vein occlusion with intravitreal tissue plasminogen activator and intravitreal triamcinolone(2004)6 cited
- Combined Central Retinal Artery & Central Retinal Vein Occlusion in Secondary APS(2015)